Grade My Investments
HomeFree Stock Grades › ANAB

AnaptysBio, Inc. (ANAB) Stock Grade

ANAB · Healthcare

A+
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$898.1M
P/E Ratio
Revenue Growth (YoY)
+157.0%
Net Margin
-5.6%
Return on Equity
Dividend Yield
None

About AnaptysBio, Inc.'s fundamentals

AnaptysBio is a biotechnology company with an $898.1 million market capitalization that reported exceptional revenue growth of 157% year-over-year, indicating rapidly expanding commercial traction. Despite this strong top-line expansion, the company operates at a net loss with a -5.6% net margin, reflecting typical cash burn patterns for growth-stage biotech firms. Notably, the company generated positive free cash flow in its latest period despite reporting an accounting loss, suggesting operational improvements and potential progress toward cash flow breakeven. The company does not currently pay a dividend.

Track ANAB free — no credit card required. Live grade + monthly AI report →